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Interleukin-17 in Various Ocular Surface Inflammatory Diseases
Recently, the association of Th-17 cells or IL-17 with ocular inflammatory diseases such as 
uveitis, scleritis and dry eye syndrome was discovered. We assessed whether interleukin 
(IL)-17 was present in the tears of various ocular surface inflammatory diseases and the tear 
IL-17 concentrations were clinically correlated with various ocular surface inflammatory 
diseases. We measured concentrations of IL-17 in tears of normal subjects (n = 28) and 
patients (n = 141) with meibomian gland dysfunction (MGD), dry eye syndrome (DES), 
Sjögren syndrome (SS), Stevens-Johnson syndrome (SJS), graft-versus-host disease (GVHD), 
filamentary keratitis, and autoimmune keratitis associated with rheumatoid arthritis or 
systemic lupus erythematosus. Clinical epitheliopathy scores were based on the surface 
area of corneal and conjunctival fluorescein staining. The mean concentrations of IL-17 in 
tears of patients with filamentary keratitis, GVHD, autoimmune keratitis, SS, DES, MGD, 
SJS were significantly higher in order than that in normal subjects. Tear IL-17 concentration 
was significantly correlated with clinical epitheilopathy scores in the patients with systemic 
inflammatory disease, while tear IL-17 was not correlated with clinical severity of the 
cornea and conjunctiva in the dry eye patients without any systemic inflammatory disease. 
Tear IL-17 is likely to correlate clinically with corneal disease severity only in the patients 
with systemic inflammatory disease.
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INTRODUCTION
Since a distinct T cell subset, known as T helper type 17 lympho-
cyte (Th-17), which is characterized by the production of inter-
leukin (IL)-17 has been identified (1, 2), compelling evidence 
has accumulated that Th-17 cells are involved in a wide variety 
of autoimmune (3-8) and allergic diseases (9) and transplanta-
tion rejection (10). Recent studies have indicated that Th-17 cells 
are involved in psoriasis (3), rheumatoid arthritis (RA) (4), mul-
tiple sclerosis (MS) (5), inflammatory bowel disease (IBD) (6), 
systemic lupus erythematosus (SLE) (7) and asthma (9), through 
the IL-17/IL-23 axis.
  Currently, the association of Th-17 cells or IL-17 with ocular 
inflammatory diseases such as uveitis (11, 12) and scleritis (12), 
as well as dry eye syndrome (13, 14), has also been revealed. In 
addition, Th-17 cells have been found to play an important role 
in early herpes virus-induced corneal inflammation (15).
  IL-17, which is mainly produced by Th-17 cells, mediates pow-
erful effects on stromal cells, resulting in production of inflam-
matory cytokines and recruitment of leukocytes, especially neu-
trophils, thus creating a link between innate and adaptive im-
munity (2). The IL-17 associated modulation of stromal cells 
may have an affect on conjunctival and corneal wound healing 
in various ocular surface inflammatory diseases, leading to epi-
thelial erosion, which the clinician assesses for clinical scoring 
and disease severity.  
  For this study, we hypothesized that Th-17 cells might be in-
volved to different degrees not only in autoimmune ocular sur-
face disease but also in nonautoimmune ocular surface disease. 
We also presumed that the involvement of Th-17 cells could be 
correlated with clinical scores of ocular surfaces, which repre-
sent disease severity. Therefore, we aimed to quantify IL-17 in 
the tears of various ocular surface inflammatory diseases, and 
to assess whether there were clinical correlations of tear IL-17 
concentration with various ocular surface inflammatory dis-
eases.
MATERIALS AND METHODS
Subjects
Patients visiting the outpatient clinic of Seoul National Univer-
sity Hospital between March and October 2009, and who pre-
sented with various ocular surface diseases, were enrolled (n = 
142). Normal subjects without any ocular problems and system-
ic diseases voluntarily participated as controls (n = 28). Ocular 
surface disease was diagnosed by an ophthalmologist. Kang MH, et al.  •  Interleukin-17 in Tears
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  The included ocular surface diseases were as follows: meibo-
mian gland dysfunction (MGD, n = 51), dry eye syndrome with-
out any systemic disease and meibomian gland dysfunction 
(DES, n = 38), Sjögren syndrome (SS, n = 33), chronic limbal de-
ficiency secondary to Stevens-Johnson syndrome (SJS, n = 5), 
DES with rheumatoid arthritis (RA) or systemic lupus erythe-
matosus (SLE, n = 4), graft-versus-host disease (GVHD, n = 7), 
and filamentary keratitis (n = 3). Patients taking oral or topical 
steroids or topical cyclosporine eye drops within one month 
before enrollment were excluded. 
  Patient characteristics are summarized in Table 1. There were 
141 patients (23 males) included in the study, with a mean age 
of 52.6 yr. 
  The patients were divided into two groups; subjects without 
systemic inflammatory disease (group A) and the others with 
systemic inflammatory disease (group B). Group A included 
simple dry eye, MGD and filamentary keratitis, while group B 
included GVHD, SS, SJS, dry eye with RA or SLE. Tear IL-17 con-
centration were compared among the disease in each group, and 
the correlation of tear IL-17 with clinical severity of the cornea 
were analyzed in each group.
Measurement of tear IL-17 concentrations 
A previously reported protocol was followed for sampling tears 
(16). Topical anesthetics was not used to avoid diluting effect 
before collecting tear. To avoid reflex tearing, Schirmer strip was 
carefully placed not to irritate conjunctival surface as possible as 
we could. Tears were collected for 5 min by the Schirmer I meth-
od using filter paper (Color Bar Schirmer Tear Test standardized 
sterile strips, Eagle Vision, Inc., Memphis, TN, USA) in the same 
exam room to minimize the effect of ambient humidity. After 
collection, each Schirmer strip was stored at -20°C until use. For 
evaluation, each Schirmer strip was thawed and the tear volume 
was calculated by converting 1 mm of tear-moistened Schirmer 
strip to 1 μL of tear volume (16). The strip was eluted at room 
temperature overnight with a final volume of 0.05 M phosphate-
buffered solution (PBS, pH 7.2) containing 0.5 M NaCl, and 0.5% 
Tween 20, such that the tear sample was diluted to 40-fold.
  Tear concentrations of IL-17A were measured using a com-
mercially-available enzyme-linked immunosorbent assay (ELI-
SA) kit (Human IL-17 DuoSet; R&D Systems, Minneapolis, MN, 
USA) according to manufacturer instructions. ELISAs were per-
formed in triplicate to ensure the reproducibility of the data. 
According to the manufacturer, the assay’s lower limit of detec-
tion was 15 pg/mL.
Clinical scoring of ocular surface epitheliopathy 
Clinical scoring was based on the area of corneal and conjunc-
tival fluorescein staining (17), and was modified according to 
the protocol of the study clinic. One drop of 2% sterile fluores-
cein was instilled into each conjunctival sac, and after the pa-
tient blinked several times, corneal and conjunctival staining 
were scored as quickly as possible. There were 3 corneal regions 
(upper, middle, and lower) and 4 conjunctival regions (superi-
Table 1. Demographic characteristics of study subjects
Groups
Number 
of  
patients
Sex ratio 
(percent  
female %)
Age (yr) Clinical scores
Normal 28   75.0 38.32 ± 16.12 0
MGD 51   76.5 60.94 ± 12.39 0.19 ± 0.69
Sjögren 33 100.0 50.10 ± 12.48 1.69 ± 1.33
GVHD   7   42.8 40.70 ± 14.41   2.0 ± 1.15
Autoimmune keratitis   4 100 50.30 ± 8.85 0.5 ± 1.0
DES 38   89.5 51.10 ± 15.22   0.5 ± 0.86
Filamentary keratitis   3   66.7 56.00 ± 32.14 2.67 ± 1.15
SJS   5   60.0 47.20 ± 12.58   2.8 ± 1.09
MGD, meibomian gland dysfunction; Sjögren, Sjögren syndrome; GVHD, graft-versus 
host disease; Autoimmune keratitis, dry eye syndrome with Rheumatic arthritis or 
Systemic lupus erythematosus; DES, dry eye syndrome without systemic disease; 
SJS, Stevens-Johnson syndrome.
A D C B
E H G F
Fig. 1. Photograph standards and diagram for clinical scoring of corneal and conjunctival staining, with fewer modifications. Corneal staining standards; (A, B) and (C) each are 
1 point; (D) and (E) each are 2 points; (F) and (G) each are 3 points. (H) Diagram: fluorescein staining was recorded in upper, middle and lower corneal regions; and superior, 
inferior, nasal, and temporal conjunctival regions.Kang MH, et al.  •  Interleukin-17 in Tears
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or, inferior, nasal, and temporal) evaluated (Fig. 1). A maximum 
of 3 points was used for corneal fluorescein staining as follows: 
0 point for no punctuate staining of the cornea; 1 point for cor-
neal epithelial staining in 1 region or less, 2 points for 2 regions 
or less, but more than 1 region, 3 points for more than 2 regions 
(Fig. 1).
  A maximum of 3 points was also used for conjunctival fluo-
rescein staining as follows: 0 point for no punctuate staining of 
the conjunctiva; 1 point for conjunctival staining in 1 quadrant 
or less, 2 points for 2 quadrants, and 3 points for 3 or more quad-
rants of conjunctival staining. Clinical scores were calculated by 
adding the corneal and conjunctival scores, with a maximum 
score of 6 points (18). 
Statistical analysis 
To compare the mean IL-17 concentration in tears of normal 
subjects with the mean concentrations in tears of the disease 
groups, a nonparametric statistical test (Mann-Whitney U test) 
was used. The Pearson correlation analysis test was used to as-
sess the relationship between clinical scores and IL-17 concen-
trations in tears. For all tests, P < 0.05 was considered to be sig-
nificant.
Ethics statement 
This study was approved by the institutional review board of 
Seoul National University Hospital (H-0803-029-238). All sub-
jects signed informed consent forms for participation in this 
study.
 
RESULTS
The demographics of the patients were shown in Table 1. The 
score in corneal severity were higher in SJS, filamentary kerati-
tis, GVHD and SS in order (Table 1).  
  An aim of this study was to evaluate whether IL-17 is involved 
in various ocular surface inflammations. Surprisingly, most oc-
ular surface diseases, including not only autoimmune-associ-
ated keratitis but also non-autoimmune surface inflammation, 
showed increased tear IL-17 concentrations, suggesting possi-
ble involvement of Th-17 cells. The mean concentrations of tear 
IL-17A in patients with GVHD, SS, autoimmune keratitis, MGD, 
DES, and filamentary keratitis were significantly higher than the 
mean concentration of IL-17A in normal subjects (Table 2 and 
Fig. 2, P < 0.05, Mann-Whitney U test). The mean concentration 
of tear IL-17A was highest in filamentary keratitis, followed in 
Table 2. The concentrations of the tear IL-17 in the various ocular surface diseases (pg/mL)
Groups   Mean Standard deviation   Minimum   Maximum   Median
Normal  45.35 57.46  15.00 200.20 15.00
MGD  389.98 244.92  35.71  969.06 336.65
Sjögren  530.43 446.32 35.44  2,162.27 418.27
GVHD  845.23 391.11  222.08 1,455.10 908.22
Autoimmune keratitis  542.31 421.24  124.05 1,122.14 525.32
DES  422.98 389.77 39.76 1,740.43 279.78
Filamentary keratitis 1,102.04 859.71  232.78 1,998.70 1,022.63
SJS  356.79  223.74  141.99 728.16 328.89
MGD, meibomian gland dysfunction; Sjögren, Sjögren syndrome; GVHD, graft-versus host disease; Autoimmune keratitis, dry eye syndrome with Rheumatic arthritis or Systemic 
lupus erythematosus; DES, dry eye syndrome without systemic disease; SJS, Stevens-Johnson syndrome.
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Fig. 2. Mean values of IL-17 concentrations in tears of each patient group compared to the normal control group. The patients were divided into two groups; subjects without 
systemic inflammatory disease (A, group A) and the others with systemic inflammatory disease (B, group B). In all groups, the mean concentrations of IL-17 were significantly 
higher than that of the normal group (Mann-Whitney U test). NL, normal control; MGD, meibomian gland dysfunction; Sjogren, Sjögren syndrome; GVHD, graft-versus host dis-
ease; Autoimmune, dry eye syndrome associated with rheumatoid arthritis or systemic lupus erythematosus; DES, dry eye syndrome without systemic disease; SJS, Stevens-
Johnson syndrome; Keratitis, filamentary keratitis.Kang MH, et al.  •  Interleukin-17 in Tears
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order of decreasing concentrations by GVHD, autoimmune ker-
atitis, SS, DES, MGD and SJS. Interestingly, the mean concen-
tration of IL-17A in GVHD patients was higher than in DES, SJS 
and SS patients (P = 0.007, 0.032, and 0.031, Mann-Whitney U 
test, Fig. 3). 
  While, correlates tear IL-17 concentrations with clinical scores 
of ocular surface inflammation, it could provide clinically rele-
vant information. As shown in Fig. 4, tear IL-17 concentrations 
significantly correlated with clinical scores in patients with sys-
temic inflammatory disease, (Pearson correlation coefficient [r] = 
0.364, P = 0.022, Pearson correlation analysis test) on the contrary, 
tear IL-17 did not correlate with the clinical severity in the dry 
eye patients without any systemic inflammatory disease (Pear-
son correlation coefficient [r] = 0.012, P = 0.901, Pearson corre-
lation analysis test) although high tear IL-17 was shown in these 
patients. To rule out age as a confounding factor, age was ana-
lyzed in relation to tear IL-17 concentrations, and there was no 
significant correlation (Pearson correlation coefficient [r] = -0.037, 
P = 0.637, Pearson correlation analysis test, Fig. 5). It suggested 
that tear IL-17 is likely to be clinically involved in corneal inflam-
mation in the patients with systemic inflammatory disease.
DISCUSSION
The demonstration of IL-17 involvement in various ocular sur-
face diseases is supporting evidence for recent reports (13, 19) 
showing that Th-17 cells are important in the pathogenesis of 
ocular surface diseases. We demonstrated in this study that ele-
vated tear IL-17 levels were seen in not only autoimmune-asso-
ciated but also non-autoimmune-associated ocular surface dis-
eases, including meibomian gland disease and dry eye syndrome. 
However, the concentrations of IL-17 correlated well with clini-
cal scoring of epitheliopathy only in the patients with systemic 
inflammatory disease, indicating that tear IL-17 expression lev-
els can provide clinically-relevant information on corneal dis-
ease severity in the patients with systemic autoimmune disease 
and systemic inflammatory disease like GVHD.  
Fig. 3. Mean values of IL-17 concentrations in tears of each patient group compared 
to the Graft-versus-host disease patients. The mean IL-17 concentration of graft-ver-
sus-host disease patients was significantly higher than those of dry eye syndrome 
without systemic disease patients, Stevens-Johnson syndrome and Sjögren syndrome 
patients (Mann-Whitney U test). GVHD, graft-versus-host disease; DES, dry eye syn-
drome without systemic disease; SJS, Stevens-Johnson syndrome; Sjogren, Sjögren 
syndrome.
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Fig. 4. Correlation of tear IL-17 concentrations with clinical scores. There was no correlation of tear IL-17 with clinical scores in subjects the dry eye patients without systemic 
disease (group A; (A) Pearson correlation coefficient [r] = 0.012, P = 0.901) while, tear IL-17 did correlate a statistically significantly positive correlation with clinical severity in 
the patients with systemic diseases (group B; (B) Pearson correlation coefficient [r] = 0.364, P = 0.002).
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Fig. 5. Simple scatter graph of ages and IL-17 concentrations. There was no correla-
tion between age and IL-17 concentrations (P = 0.637, r = Pearson correlation coef-
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  The discovery of specific cells and cytokines with pivotal roles 
in inflammation can lead to the development of targeted thera-
py to selectively inhibit critical steps, with minimal side effects. 
Chauhan et al. (13) showed that in vivo blockade of IL-17 signif-
icantly reduced the severity and progression of disease. Fortu-
nately, eyes can be treated topically, thereby avoiding systemic 
toxicity. Because of this, recent excellent work on the role of Th-
17 cells in ocular surface disease could in the near future lead to 
the development of topical IL-17-targeted therapy that acts by 
interfering with local Th-17 cell activity.
  Actually, the ocular surface has a Th-17 cell differentiation-
friendly environment enriched with cytokines, including TGF- 
β1, IL-6, IL-23, and IL-1β induced by certain stimuli (14, 19, 20). 
Zheng et al. (19) showed that corneal epithelial cells that are ex-
posed to hyperosmotic, microbial, and inflammatory stimuli 
secreted cytokines promoting Th-17 cell differentiation. Our clin-
ical data also suggest that Th-17 cells may be crucial in various 
ocular surface inflammations, especially in systemic inflamma-
tory disease. The in vivo correlation of IL-17 with clinical scores 
of epithelial cell injury in the patients with systemic inflamma-
tory disease strongly supports the results of Zheng’s in vitro ex-
periments that damaged epithelial cells might enhance Th-17 
cell differentiation (19). In addition, IL-17 is known to induce 
epithelial, stromal and immune cells to secrete proinflamma-
tory cytokines such as IL-6, TNF-α, IL-1, and IL-8 (21) and dis-
ruptive enzymes such as metalloproteinase-9 (14). A vicious 
cycle may develop in which a high IL-17 concentration is main-
tained in an ocular environment with damaged epithelial cells 
that have already produced proinflammatory cytokines. 
  As mentioned in the introduction, autoimmune diseases such 
as Sjögren syndrome, rheumatoid arthritis, and systemic lupus 
erythematosus, which often involve the ocular surface, are re-
lated to Th-17 cells. In fact, serum levels of IL-17 have been re-
ported to correlate with both the activity and severity of these 
autoimmune diseases (22, 23). Subsequently, ocular involve-
ment of IL-17 in these diseases may well be expected, which was 
clearly seen in the results of our study. Moreover, we found that 
serum IL-17 was also elevated in patients with GVHD, Sjögren 
syndrome- and rheumatoid arthritis-associated dry eye (24). In 
that previous study, the serum IL-17 level correlated significant-
ly with the fluorescein staining score in these patients with sys-
temic inflammatory disease, which corresponded well with this 
study showing correlation of tear IL-17 with clinical severity of 
the cornea. Therefore, on top of this previous evidence, the fact 
that correlation of the tear IL-17 with clinical severity strongly 
suggested that IL-17 might be involved in corneal surface inflam-
mation in systemically autoimmune disease patients. Therefore, 
taking into consideration these previous reports including our 
study (22, 23), clinical correlation of tear IL-17 concentrations 
with ocular surface damage scores may be a valuable approach 
for assessing disease severity, providing the chance of bypass of 
lacrimal biopsy in Sjögren’s syndrome. 
  Another interesting finding in this study was that chronic oc-
ular GVHD showed a markedly high concentration of tear IL-17 
compared with autoimmune and nonautoimmune ocular sur-
face disorders. To the best of our knowledge, this is the first find-
ing of IL-17 in ocular GVHD. Th-17 cells are known to mediate 
systemic GVHD (25, 26) although the exact role of Th-17 is still 
debated (27). The reason why ocular GVHD presented with high 
IL-17 values is still unclear. It can be presumed that it may be 
caused by direct invasion of host Th-17 cells as well as by dam-
aged ocular epithelial cells inducing Th-17 cell differentiation 
from recruited naïve T cells. Further investigation is needed to 
elucidate the exact mechanisms for GVHD ocular IL-17.  
  While, the simple dry eye and MGD did not present significant 
correlation between the tear IL-17 and clinical severity, although 
high concentration of tear IL17 was observed compared with 
control. The reason why this disparity happened might be con-
densing effect of tear as tear evaporated. That is, the condensed 
concentration of tear might include condensed concentration 
of IL-17. To clarify condensing effect of tear IL-17 due to tear 
evaporation, additional analysis for the abundant tear keeping 
protein like lactoferrin in normal condition as a control. The 
change of tear IL-17 would be analyzed after adjustment of lac-
toferrin to exclude condensing effect. Although this study was 
limited that additional protein data could not be analyzed to 
adjust condensing effect due to small volume of the tear, our 
study is still worthy of notice to understand role of IL-17 in not 
only simple dry eye but also keratitis with systemic autoimmune 
disease. That is, our data suggested that tear IL-17 might be clin-
ically relevant in systemic autoimmune disease patients to as-
sess disease severity, while tear IL-17 might not be clinically rel-
evant in simple evaporated type of dry eye. 
  On the other hand, the simple dry eye and MGD did not show 
severe clinical scores, in contrast dry eye with systemic disease 
presented wide range of clinical scores from mild type to very 
severe type. Simple dry eye or MGD seemed not to accompany 
severe corneal epithelial lesion. Considering that there is a cer-
tain possibility that damaged cells per se would enhance IL-17 
production by CD4 T cells (28), the explanation the other way 
around would be plausible. That is, the more cells are injured, 
the production of IL-17 appeared to be the more affected. That 
might be a reason why simple dry eye with rather low clinical 
scores did not show any relation with IL-17. 
  A limitation of this study is the relatively small number of pa-
tients in the autoimmune-associated ocular surface disease 
groups. Another limitation is that we did not identify the cells 
secreting IL-17. Although the main source of IL-17 is Th-17 cells, 
in minor amounts it can also be produced by CD8
+ T cells, γδT 
cells, natural killer T (NKT) cells, neutrophils, eosinophils, and 
macrophages (8, 29, 30). IL-17A is the prototypical member of 
the IL-17 family, which consists of six related proteins, from IL-Kang MH, et al.  •  Interleukin-17 in Tears
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17A to IL-17F. Th-17 cells are the major source of IL-17A and F, 
while other cell populations express IL-17A to a lesser extent. As 
a result, assessment of IL-17A indicates that Th-17 cells are more 
likely to be the source cells than other cell populations. Conse-
quently, our measurement of IL-17A can to some extent justify 
our assumption that Th-17 cells were the source cells but this 
correlation certainly needs further investigation. Another limi-
tation was that we could not control unseen microscopic reflex 
tearing completely during the examination. However, when the 
gross reflex tearing was observed, we removed Schirmer strip, 
wait 10-20 min, and then re-applied it to exclude most gross re-
flex tearing as possible as we could. In fact, one of the other lim-
itation was that age was significantly younger in volunteering 
control group than the diseased group. Although we confirmed 
that age was not a confounding factor of IL-17 level using Pear-
son correlation test, it could still act a little bit as a bias factor. 
Nontheless, we still believe our findings may contribute to the 
further understanding of ocular surface disease pathogenesis 
regarding involvement of IL-17.
  In conclusion, tear IL-17 is likely to be associated with the dry 
eye in the patients with systemic autoimmune diseases or sys-
temic inflammatory disease by showing concentrations of IL-17 
correlated well with clinical severity of the cornea. This suggests 
that Th-17 cells may be involved in the pathogenesis of ocular 
surface inflammatory disease. Clinically, the measurement of 
the concentration of IL-17 in tear may be applied as a valuable 
option to evaluate the ocular surface inflammatory severity quan-
titatively in the patients with systemic inflammatory disease.
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AUTHOR SUMMARY
Interleukin-17 in Various Ocular Surface Inflammatory Diseases
Min Ho Kang, Mee Kum Kim, Hyun Joo Lee, Hyeon Il Lee, Won Ryang Wee and Jin Hak Lee
We measured concentration of interleukin (IL)-17 in patients’ tears and found that the tear IL-17 is increased in various ocular 
surface diseases. Interestingly, in the patients with systemic autoimmune diseases or with systemic inflammatory disease, 
concentrations of IL-17 are positively correlated with clinical severity of the cornea. Our results suggest that Th-17 cells are 
involved in the pathogenesis of ocular surface inflammatory disease. Clinically, the measurement of tear IL-17 could be applied as 
a parameter for quantitative evaluation of ocular surface inflammation.